Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

Savara Presented New Biomarker Data From the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2026

Summary by Joplin Globe
LANGHORNE, Pa.--(BUSINESS WIRE)--May 20, 2026-

2 Articles

Joplin GlobeJoplin Globe
Center

Savara Presented New Biomarker Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2026

LANGHORNE, Pa.--(BUSINESS WIRE)--May 20, 2026-

Read Full Article
Enid News & EagleEnid News & Eagle
Lean Left

Savara Presented Long-Term Efficacy and Safety Data from the Ongoing IMPALA-2 Phase 3 Clinical Trial Open-Label (OL) Extension of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

LANGHORNE, Pa.--(BUSINESS WIRE)--May 19, 2026-

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 50% of the sources lean Left, 50% of the sources are Center
50% Center

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

Enid News & Eagle broke the news on Tuesday, May 19, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

Langhorne icon

Langhorne

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal